In this study, we enrolled 107,776 people with SARS-CoV-2 infection — including 11,588 users of SGLT2 inhibitors and 96,188 users of other antihyperglycemics — and followed them for a median of 1.57 (IQR: 1.05–2.49) years after infection which altogether corresponded to 184,563 person-years of follow up. This evidence concerns the gene SLC5A2 and infection.